LEAMINGTON SPA, England, Sept. 10, 2013 /PRNewswire/ -- Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) ...

-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Researchers have observed a “modest uptake” in the use of biosimilars for infliximab in the past 18 ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved INFLECTRA™ (biosimilar infliximab) ...

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by ...

Pfizer announced today that it will begin shipping INFLECTRA® (infliximab-dyyb) for injection, a biosimilar of REMICADE® (infliximab), to wholesalers in the United States (U.S.) in late November 2016.

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who switched from Remicade to Inflectra showed no differences in drug ...

inflectra-approved-RA-psoriasis-crohns-CA0416 The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis. The FDA has approved the biosimilar Inflectra ...

The ACR has issued an official statement regarding the FDA's approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for ...

On April 5, 2016, the FDA approved Celltrion's application to market a biosimilar to Janssen Biotech Inc.'s REMICADE ® (infliximab) anti-TNF-α antibody (see "FDA Approves Inflectra - Celltrion's ...

The US Food and Drug Administration (FDA) today approved a biosimilar version of infliximab (Remicade, Janssen Biotech) called infliximab-dyyb (Inflectra, Janssen Biotech) that treats gastrointestinal ...